Literature DB >> 26053072

Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.

Jin Su1, Alexandra Sherman2, Phillip A Doerfler2, Barry J Byrne2, Roland W Herzog2, Henry Daniell1.   

Abstract

Deficiency of acid alpha glucosidase (GAA) causes Pompe disease in which the patients systemically accumulate lysosomal glycogen in muscles and nervous systems, often resulting in infant mortality. Although enzyme replacement therapy (ERT) is effective in treating patients with Pompe disease, formation of antibodies against rhGAA complicates treatment. In this report, we investigated induction of tolerance by oral administration of GAA expressed in chloroplasts. Because full-length GAA could not be expressed, N-terminal 410-amino acids of GAA (as determined by T-cell epitope mapping) were fused with the transmucosal carrier CTB. Tobacco transplastomic lines expressing CTB-GAA were generated through site-specific integration of transgenes into the chloroplast genome. Homoplasmic lines were confirmed by Southern blot analysis. Despite low-level expression of CTB-GAA in chloroplasts, yellow or albino phenotype of transplastomic lines was observed due to binding of GAA to a chloroplast protein that has homology to mannose-6 phosphate receptor. Oral administration of the plant-made CTB-GAA fusion protein even at 330-fold lower dose (1.5 μg) significantly suppressed immunoglobulin formation against GAA in Pompe mice injected with 500 μg rhGAA per dose, with several-fold lower titre of GAA-specific IgG1 and IgG2a. Lyophilization increased CTB-GAA concentration by 30-fold (up to 190 μg per g of freeze-dried leaf material), facilitating long-term storage at room temperature and higher dosage in future investigations. This study provides the first evidence that oral delivery of plant cells is effective in reducing antibody responses in ERT for lysosomal storage disorders facilitating further advances in clinical investigations using plant cell culture system or in vitro propagation.
© 2015 Society for Experimental Biology, Association of Applied Biologists and John Wiley & Sons Ltd.

Entities:  

Keywords:  Pompe disease; bioencapsulation; enzyme replacement therapy; lysosomal storage disorder; molecular farming; oral tolerance

Mesh:

Substances:

Year:  2015        PMID: 26053072      PMCID: PMC4578979          DOI: 10.1111/pbi.12413

Source DB:  PubMed          Journal:  Plant Biotechnol J        ISSN: 1467-7644            Impact factor:   9.803


  64 in total

Review 1.  Molecular strategies for gene containment in transgenic crops.

Authors:  Henry Daniell
Journal:  Nat Biotechnol       Date:  2002-06       Impact factor: 54.908

2.  Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria.

Authors:  M Rescigno; M Urbano; B Valzasina; M Francolini; G Rotta; R Bonasio; F Granucci; J P Kraehenbuhl; P Ricciardi-Castagnoli
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

3.  Biopharmaceutical benchmarks 2014.

Authors:  Gary Walsh
Journal:  Nat Biotechnol       Date:  2014-10       Impact factor: 54.908

4.  Low-cost production of proinsulin in tobacco and lettuce chloroplasts for injectable or oral delivery of functional insulin and C-peptide.

Authors:  Diane Boyhan; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2010-12-08       Impact factor: 9.803

5.  Mapping the T helper cell response to acid α-glucosidase in Pompe mice.

Authors:  Sushrusha Nayak; Ramya Sivakumar; Ou Cao; Henry Daniell; Barry J Byrne; Roland W Herzog
Journal:  Mol Genet Metab       Date:  2012-03-23       Impact factor: 4.797

6.  Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.

Authors:  Baodong Sun; Andrew Bird; Sarah P Young; Priya S Kishnani; Y-T Chen; Dwight D Koeberl
Journal:  Am J Hum Genet       Date:  2007-09-21       Impact factor: 11.025

7.  Engineering the chloroplast genome for hyperexpression of human therapeutic proteins and vaccine antigens.

Authors:  Shashi Kumar; Henry Daniell
Journal:  Methods Mol Biol       Date:  2004

8.  Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites.

Authors:  M M Hermans; H A Wisselaar; M A Kroos; B A Oostra; A J Reuser
Journal:  Biochem J       Date:  1993-02-01       Impact factor: 3.857

9.  Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells.

Authors:  Alexandra Sherman; Jin Su; Shina Lin; Xiaomei Wang; Roland W Herzog; Henry Daniell
Journal:  Blood       Date:  2014-05-13       Impact factor: 22.113

10.  Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts.

Authors:  H Daniell; S B Lee; T Panchal; P O Wiebe
Journal:  J Mol Biol       Date:  2001-08-31       Impact factor: 5.469

View more
  31 in total

Review 1.  Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.

Authors:  Laura I Salazar-Fontana; Dharmesh D Desai; Tarik A Khan; Renuka C Pillutla; Sandra Prior; Radha Ramakrishnan; Jennifer Schneider; Alexandra Joseph
Journal:  AAPS J       Date:  2017-01-12       Impact factor: 4.009

Review 2.  Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review.

Authors:  Ankit K Desai; Cindy Li; Amy S Rosenberg; Priya S Kishnani
Journal:  Ann Transl Med       Date:  2019-07

3.  Oral Tolerance: Another Reason to Eat Your Veggies!

Authors:  Romain Hardet; Federico Mingozzi
Journal:  Mol Ther       Date:  2017-01-18       Impact factor: 11.454

Review 4.  Edible plants for oral delivery of biopharmaceuticals.

Authors:  Matilde Merlin; Mario Pezzotti; Linda Avesani
Journal:  Br J Clin Pharmacol       Date:  2016-05-09       Impact factor: 4.335

Review 5.  Vaccination via Chloroplast Genetics: Affordable Protein Drugs for the Prevention and Treatment of Inherited or Infectious Human Diseases.

Authors:  Henry Daniell; Hui-Ting Chan; Elise K Pasoreck
Journal:  Annu Rev Genet       Date:  2016-10-21       Impact factor: 16.830

Review 6.  Expression and functional evaluation of biopharmaceuticals made in plant chloroplasts.

Authors:  Bei Zhang; Balamurugan Shanmugaraj; Henry Daniell
Journal:  Curr Opin Chem Biol       Date:  2017-02-23       Impact factor: 8.822

7.  Advances in molecular farming: key technologies, scaled up production and lead targets.

Authors:  Henry Daniell; Stephen J Streatfield; Edward P Rybicki
Journal:  Plant Biotechnol J       Date:  2015-10       Impact factor: 9.803

8.  Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy.

Authors:  A Broomfield; J Fletcher; J Davison; N Finnegan; M Fenton; A Chikermane; C Beesley; K Harvey; E Cullen; C Stewart; S Santra; S Vijay; M Champion; L Abulhoul; S Grunewald; A Chakrapani; M A Cleary; S A Jones; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2015-10-26       Impact factor: 4.982

9.  Low-cost oral delivery of protein drugs bioencapsulated in plant cells.

Authors:  Kwang-Chul Kwon; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2015-09-03       Impact factor: 9.803

Review 10.  The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders.

Authors:  A Broomfield; S A Jones; S M Hughes; B W Bigger
Journal:  J Inherit Metab Dis       Date:  2016-02-16       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.